ALC logo

Alcon Inc. Stock Price

SWX:ALC Community·CHF 27.9b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 36 Fair Values set on narratives written by author

ALC Share Price Performance

CHF 0
-73.62 (-100.00%)
CHF 76.62
Fair Value
CHF 0
-73.62 (-100.00%)
Price CHF 0

ALC Community Narratives

·
Fair Value CHF 76.62 25.4% undervalued intrinsic discount

Cutting Edge Eye Care Solutions Will Transform Outcomes For Global Aging Populations

0users have liked this narrative
0users have commented on this narrative
20users have followed this narrative
·
Fair Value CHF 56.59 1.0% overvalued intrinsic discount

Government Price Cuts Will Compress Margins Though Telemedicine Supports

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
·
Fair Value CHF 88.89 35.7% undervalued intrinsic discount

Unity VCS And LumiThera Will Drive Global Eye Care Transformation

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
CHF 56.59
1.0% overvalued intrinsic discount
Revenue
5.87% p.a.
Profit Margin
9.18%
Future PE
32.18x
Price in 2029
CHF 64.53
CHF 76.62
25.4% undervalued intrinsic discount
Revenue
6.34% p.a.
Profit Margin
13%
Future PE
30.64x
Price in 2029
CHF 87.49
CHF 88.89
35.7% undervalued intrinsic discount
Revenue
7.6% p.a.
Profit Margin
15.4%
Future PE
29.81x
Price in 2029
CHF 101.9

Trending Discussion

No trending discussion available.

Updated Narratives

ALC logo

ALC: Buybacks And New Lens Collaboration Will Shape A Measured Outlook

Fair Value: CHF 56.59 1.0% overvalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
ALC logo

ALC: Cataract Platform Expansion And Share Buybacks Will Drive Future Upside

Fair Value: CHF 76.62 25.4% undervalued intrinsic discount
20 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
ALC logo

ALC: Share Buybacks And New Eye Care Launches Will Support Upside

Fair Value: CHF 88.89 35.7% undervalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet and fair value.

1 Risk
3 Rewards

Alcon Inc. Key Details

US$10.6b

Revenue

US$4.7b

Cost of Revenue

US$6.0b

Gross Profit

US$5.2b

Other Expenses

US$819.0m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 11, 2026
1.68
56.14%
7.70%
21.4%
View Full Analysis

About ALC

Founded
1945
Employees
25000
CEO
David Endicott
WebsiteView website
www.alcon.com

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Recent ALC News & Updates

Narrative Update Jul 21

ALC: Buybacks And New Lens Collaboration Will Shape A Measured Outlook

Analysts have trimmed their Alcon price target to CHF56.59 from CHF57.82, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margins and future P/E levels. What's in the News for Alcon Alcon and RxSight entered a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses, combining RxSight’s postoperative light-adjustable technology with Alcon’s PCIOL optical designs to allow surgeons to fine-tune vision for cataract patients after surgery.

Recent updates

No updates